医薬品受託製造開発機関(CDMO)の世界市場2019-2027

◆英語タイトル:Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Global Market Outlook (2019-2027)
◆商品コード:SMRC20OC088
◆発行会社(リサーチ会社):Stratistics MRC
◆発行日:2020年9月
◆ページ数:約150
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥448,200見積依頼/購入/質問フォーム
Five UserUSD5,250 ⇒換算¥567,000見積依頼/購入/質問フォーム
EnterprisewideUSD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Stratistics MRC社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査資料では、医薬品受託製造開発機関(CDMO)の世界市場を広く調査・分析し、エグゼクティブサマリー、序文、市場動向分析、ファイブフォース分析、研究フェーズ別分析(フェーズI、フェーズII、フェーズIII、フェーズIV、前臨床)、サービスタイプ別分析(医薬品製造サービス、生物製剤製造サービス、医薬品開発サービス)、エンドユーザー別分析(中小規模製薬会社、大規模製薬会社、ジェネリック製薬会社)、地域別分析情報、主要な市場開拓、企業情報など、以下の構成でまとめております。     
・エグゼクティブサマリー
・序文
・市場動向分析
・ファイブフォース分析
・医薬品受託製造開発機関(CDMO)の世界市場規模:研究フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV、前臨床)
・医薬品受託製造開発機関(CDMO)の世界市場規模:サービスタイプ別(医薬品製造サービス、生物製剤製造サービス、医薬品開発サービス)
・医薬品受託製造開発機関(CDMO)の世界市場規模:エンドユーザー別(中小規模製薬会社、大規模製薬会社、ジェネリック製薬会社)
・医薬品受託製造開発機関(CDMO)の世界市場規模:地域別
・主要な市場開拓
・企業情報
【レポートの概要】

According to Stratistics MRC, the Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is accounted for $148.50 billion in 2019 and is expected to reach $298.07 billion by 2027 growing at a CAGR of 9.1% during the forecast period. Some of the key factors propelling the market growth include growing demand for generic medicines and biologics, growing need for state-of-the-art processes and production technologies, advent of contract development & manufacturing organization (CDMO) model, and growing investment in R&D. However, stringent government regulations are likely to hamper the market.

The contract development and manufacturing organization (CDMO) industry had begun decades ago as a niche business by offering specialty services and manufacturing capacities to pharmaceutical companies. CDMOs also play a critical role in offering additional capacities and mitigate the risk of supply shortages by providing additional manufacturing and development sites and backup facilities. Issues regarding documentation and quality of drug manufacturing process during regulatory reviews can lead to delay in marketing authorization. Therefore for pharmaceutical companies, a prompt quality standard with proven reliability is a definitive key for outsourcing to CDMOs.

By service type, pharmaceutical manufacturing services segment is projected to grow at the lucrative rate during the forecast period, due to the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, growing demand for generic drugs, high cost of operations, and lack of in-house manufacturing capacity.

On the basis of geography, Asia-Pacific is expected to witness the significant market growth during the forecast period, owing to the low cost offered by the region, as compared to the United States and other developed economies. Additionally, growing incidences of chronic and lifestyle diseases, such as diabetes and heart disease, coupled with ease of patient recruitment and availability of expertise for clinical trials, are few driving factors boosting growth in the region. With the increasing privatization of clinical trials, there has been an increase in the outsourcing of research processes in developing regions like China and India.

Some of the key players in Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market include Famar SA, Boehringer Ingelheim Group, Catalent Inc., Pfizer CentreSource, CMIC Holdings Co. Ltd, Aenova Holding GmbH, Baxter Biopharma Solutions, Syneos Health Inc., Lonza Group , Patheon Inc., Novotech Pty Ltd, Covance Inc., Recipharm AB , SGS SA (SGS Life Sciences), Jubilant Life Sciences Ltd, Samsung Bioepis Co. Ltd, IQVIA Holdings Inc., Quanticate Ltd, PAREXEL International Corporation, and WuXi AppTec Inc.

Research Phases Covered:
• Phase I
• Phase II
• Phase III
• Phase IV
• Pre-clinical

Service Types Covered:
• Pharmaceutical Manufacturing Services
• Biologics Manufacturing Services
• Drug Development Services

End Users Covered:
• Small & Mid-size Pharma
• Big Pharma
• Generic Pharmaceutical Companies

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client’s interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Research Phase
5.1 Introduction
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV
5.6 Pre-clinical

6 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Service Type
6.1 Introduction
6.2 Pharmaceutical Manufacturing Services
6.2.1 Secondary Packaging
6.2.2 Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing
6.2.2.1 Liquid Dose Formulation
6.2.2.2 Parenteral/Injectable Dose Formulation
6.2.2.3 Solid Dose Formulation
6.2.2.4 Tablet Manufacturing Services
6.2.2.5 Capsule Manufacturing Services
6.2.3 Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing
6.3 Biologics Manufacturing Services
6.3.1 Biologics API Manufacturing
6.3.2 Biologics FDF Manufacturing
6.4 Drug Development Services

7 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By End User
7.1 Introduction
7.2 Small & Mid-size Pharma
7.3 Big Pharma
7.4 Generic Pharmaceutical Companies

8 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Famar SA
10.2 Boehringer Ingelheim Group
10.3 Catalent Inc.
10.4 Pfizer CentreSource
10.5 CMIC Holdings Co. Ltd
10.6 Aenova Holding GmbH
10.7 Baxter Biopharma Solutions
10.8 Syneos Health Inc.
10.9 Lonza Group
10.10 Patheon Inc.
10.11 Novotech Pty Ltd
10.12 Covance Inc.
10.13 Recipharm AB
10.14 SGS SA (SGS Life Sciences)
10.15 Jubilant Life Sciences Ltd
10.16 Samsung Bioepis Co. Ltd
10.17 IQVIA Holdings Inc.
10.18 Quanticate Ltd
10.19 PAREXEL International Corporation
10.20 WuXi AppTec Inc.

List of Tables
Table 1 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Region (2018-2027) ($MN)
Table 2 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)
Table 3 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)
Table 4 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)
Table 5 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)
Table 6 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)
Table 7 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)
Table 8 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)
Table 9 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)
Table 10 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)
Table 11 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)
Table 12 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)
Table 13 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)
Table 14 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)
Table 15 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)
Table 16 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)
Table 17 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)
Table 18 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)
Table 19 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)
Table 20 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)
Table 21 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)
Table 22 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)
Table 23 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)
Table 24 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)
Table 25 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)
Table 26 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)
Table 27 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)
Table 28 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)
Table 29 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)
Table 30 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)
Table 31 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)
Table 32 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)
Table 33 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)
Table 34 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)
Table 35 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)
Table 36 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)
Table 37 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)
Table 38 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)
Table 39 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)
Table 40 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)
Table 41 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)
Table 42 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)
Table 43 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)
Table 44 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)
Table 45 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)
Table 46 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)
Table 47 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)
Table 48 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)
Table 49 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)
Table 50 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)
Table 51 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)
Table 52 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)
Table 53 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)
Table 54 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)
Table 55 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)
Table 56 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)
Table 57 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)
Table 58 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)
Table 59 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)
Table 60 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)
Table 61 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)
Table 62 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)
Table 63 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)
Table 64 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)
Table 65 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)
Table 66 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)
Table 67 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)
Table 68 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)
Table 69 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)
Table 70 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)
Table 71 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)
Table 72 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)
Table 73 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)
Table 74 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)
Table 75 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)
Table 76 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)
Table 77 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)
Table 78 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)
Table 79 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)
Table 80 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)
Table 81 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)
Table 82 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)
Table 83 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)
Table 84 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)
Table 85 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)
Table 86 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)
Table 87 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)
Table 88 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)
Table 89 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)
Table 90 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)
Table 91 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)
Table 92 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)
Table 93 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)
Table 94 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)
Table 95 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)
Table 96 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)
Table 97 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)
Table 98 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)
Table 99 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)
Table 100 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)
Table 101 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)
Table 102 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)
Table 103 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)
Table 104 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)
Table 105 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)
Table 106 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)
Table 107 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)
Table 108 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)
Table 109 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)
Table 110 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)
Table 111 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)
Table 112 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)
Table 113 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)
Table 114 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)
Table 115 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)
Table 116 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)
Table 117 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)
Table 118 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)
Table 119 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)
Table 120 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[医薬品受託製造開発機関(CDMO)の世界市場2019-2027]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆